MARKET

INAB

INAB

In8Bio, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.265
+0.075
+3.42%
Closed 16:00 05/23 EDT
OPEN
2.370
PREV CLOSE
2.190
HIGH
2.370
LOW
2.180
VOLUME
14.88K
TURNOVER
20.82K
52 WEEK HIGH
10.32
52 WEEK LOW
2.000
MARKET CAP
42.67M
P/E (TTM)
-2.9057
1D
5D
1M
3M
1Y
5Y
BRIEF-In8bio Announces Data Emerging From Its Recently Unveiled Gamma-Delta T Cell "Off-The-Shelf" Induced Pluripotent Stem Cell Platform
reuters.com · 6d ago
IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform
IN8bio recently unveiled expansion of its DeltEx gamma-delta T cell platform capabilities to include induced pluripotent stem cells (iPSCs).Yesterday, at the American Society for Gene & Cell Therapy (ASGCT) 25th Annual Meeting, IN8bio announced data on its...
GlobeNewswire · 6d ago
110 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.
Benzinga · 05/16 09:23
IN8bio Q1 GAAP EPS of -$0.33
IN8bio press release (NASDAQ:INAB): Q1 GAAP EPS of -$0.33. As of March 31, 2022, the Company had cash of $32.1 million, compared to $37.0 million as of December 31, 2021. 
Seekingalpha · 05/12 12:31
BRIEF-In8bio Reports Q1 Loss Per Share Of $0.33
reuters.com · 05/12 12:15
IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today announced the Company’s new induced pluripotent stem cell (iP...
GlobeNewswire · 05/05 12:00
IN8bio to Present at May Investor and Scientific Conferences
NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced May confer...
GlobeNewswire · 05/04 12:00
Bullish IN8bio, Inc. (NASDAQ:INAB) investors are yet to receive a pay off on their US$1.0m bet
The recent 37% drop in IN8bio, Inc.'s ( NASDAQ:INAB ) stock could come as a blow to insiders who purchased US$1.0m...
Simply Wall St. · 05/03 15:00
More
No Data
Learn about the latest financial forecast of INAB. Analyze the recent business situations of In8Bio, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average INAB stock price target is 10.50 with a high estimate of 12.00 and a low estimate of 9.00.
High12.00
Average10.50
Low9.00
Current 2.265
EPS
Actual
Estimate
-0.26-0.20-0.13-0.07
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 15
Institutional Holdings: 1.82M
% Owned: 9.68%
Shares Outstanding: 18.84M
TypeInstitutionsShares
Increased
6
34.02K
New
4
108.64K
Decreased
2
3.53K
Sold Out
2
88.63K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.48%
Pharmaceuticals & Medical Research
+0.70%
Key Executives
Chairman/Director
Alan Roemer
President/Chief Executive Officer/Director/Primary Contact
William Ho
Co-Founder/Executive Vice President/Chief Scientific Officer
Lawrence Lamb
Chief Financial Officer
Patrick Mccall
Chief Operating Officer
Kate Rochlin
Vice President - Operations
Melissa Beelen
Vice President
Stacey Bilinski
Vice President
Urvashi Patel
Other
Trishna Goswami
Director
Peter Brandt
Director
Thomas Cirrito
Director
Travis Whitfill
No Data
No Data
About INAB
IN8bio, Inc. is a clinical-stage biotechnology company. The Company is focused on and developing therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The Company's product candidate includes INB-200 and INB-100. INB-200 is genetically modified autologous gamma-delta T cell product candidate that the Company is developing for the treatment of solid tumors. Its indication for INB-200 is glioblastoma (GBM). INB-100 is its allogeneic product candidate that is developed for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation (HSCT). The Company is also developing a portfolio of preclinical programs. INB-400 is its preclinical program focused on developing allogeneic cellular therapies for solid tumor cancers and INB-300 is the preclinical program focused on developing product candidates based on gamma-delta T cells with an added chimeric antigen receptor (CAR).

Webull offers kinds of IN8BIO, Inc. stock information, including NASDAQ:INAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INAB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INAB stock methods without spending real money on the virtual paper trading platform.